Craig-Hallum lowered the firm’s price target on Apyx Medical to $8 from $9 and keeps a Buy rating on the shares. Apyx’s Q4 results came in above the preliminary range provided in January, but missed consensus due to a couple stale estimates, and initial FY24 guidance is conservative given the macro and interest rate environment, but 2H24 should start to show signs of a recovery, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
